The healthcare community is buzzing by retatrutide, a new dual GIP and GLP-1 receptor that’s showing significant results in early studies . This medication works by replicating natural hormones to affect appetite and increase feelings of satiety, ultimately leading considerable body loss . While currently under investigation and not yet available